Interaction Checker

Wechselwirkungen von Epoetin alfa

Epoetin alfa (Epogen, Procrit, Retacrit) hat in den von uns erfassten FDA-Fachinformationen und Faktenblättern 249 dokumentierte Wechselwirkungen: 1 schwerwiegende, 89 mittelschwere, 159 geringfügige und 0, bei denen eine Fachinformation keine relevante Wechselwirkung berichtet. Jeder Eintrag unten zitiert den Satz, auf dem er beruht. Diese Medikamentenseite ist ein Ausgangspunkt, kein Urteil über Ihre persönliche Situation.

Wechselwirkungen laut Fachinformation

Schwerwiegende Wechselwirkungen (1)

  • AlkoholAlkoholSchwerwiegend

    …erythropoietin protein drugs [see Warnings and Precautions ( 5.6 )] Serious allergic reactions to Epogen [see Warnings and Precautions ( 5.7 )] Epogen from multiple-dose vials contains benzyl alcohol and is contraindicated in: Neonates, infants, pregnant women, and lactating women [see Warnings and Precautions ( 5.9 ), Use in Specific Populations ( 8.1 , 8.2 , 8.4 )] . (Fachinformation zu Epoetin alfa, Gegenanzeigen)

Mittelschwere Wechselwirkungen (89)

  • AcebutololBetablockerMittelschwer

    Following initiation and titration of Epogen, approximately 25% of patients on dialysis required initiation of or increases in antihypertensive therapy; hypertensive encephalopathy and seizures have been reported in patients with CKD receiving Epogen. (Fachinformation zu Epoetin alfa, Warnhinweise und Vorsichtsmaßnahmen)

  • AliskirenAntihypertensivumMittelschwer

    Following initiation and titration of Epogen, approximately 25% of patients on dialysis required initiation of or increases in antihypertensive therapy; hypertensive encephalopathy and seizures have been reported in patients with CKD receiving Epogen. (Fachinformation zu Epoetin alfa, Warnhinweise und Vorsichtsmaßnahmen)

  • Amiloridkaliumsparendes DiuretikumMittelschwer

    Following initiation and titration of Epogen, approximately 25% of patients on dialysis required initiation of or increases in antihypertensive therapy; hypertensive encephalopathy and seizures have been reported in patients with CKD receiving Epogen. (Fachinformation zu Epoetin alfa, Warnhinweise und Vorsichtsmaßnahmen)

  • AmlodipinDihydropyridin-CalciumkanalblockerMittelschwer

    Following initiation and titration of Epogen, approximately 25% of patients on dialysis required initiation of or increases in antihypertensive therapy; hypertensive encephalopathy and seizures have been reported in patients with CKD receiving Epogen. (Fachinformation zu Epoetin alfa, Warnhinweise und Vorsichtsmaßnahmen)

  • Amlodipin und AtorvastatinDihydropyridin-CalciumkanalblockerMittelschwer

    Following initiation and titration of Epogen, approximately 25% of patients on dialysis required initiation of or increases in antihypertensive therapy; hypertensive encephalopathy and seizures have been reported in patients with CKD receiving Epogen. (Fachinformation zu Epoetin alfa, Warnhinweise und Vorsichtsmaßnahmen)

  • Amlodipin und BenazeprilDihydropyridin-CalciumkanalblockerMittelschwer

    Following initiation and titration of Epogen, approximately 25% of patients on dialysis required initiation of or increases in antihypertensive therapy; hypertensive encephalopathy and seizures have been reported in patients with CKD receiving Epogen. (Fachinformation zu Epoetin alfa, Warnhinweise und Vorsichtsmaßnahmen)

  • Amlodipin und OlmesartanDihydropyridin-CalciumkanalblockerMittelschwer

    Following initiation and titration of Epogen, approximately 25% of patients on dialysis required initiation of or increases in antihypertensive therapy; hypertensive encephalopathy and seizures have been reported in patients with CKD receiving Epogen. (Fachinformation zu Epoetin alfa, Warnhinweise und Vorsichtsmaßnahmen)

  • Amlodipin und ValsartanDihydropyridin-CalciumkanalblockerMittelschwer

    Following initiation and titration of Epogen, approximately 25% of patients on dialysis required initiation of or increases in antihypertensive therapy; hypertensive encephalopathy and seizures have been reported in patients with CKD receiving Epogen. (Fachinformation zu Epoetin alfa, Warnhinweise und Vorsichtsmaßnahmen)

  • AtenololBetablockerMittelschwer

    Following initiation and titration of Epogen, approximately 25% of patients on dialysis required initiation of or increases in antihypertensive therapy; hypertensive encephalopathy and seizures have been reported in patients with CKD receiving Epogen. (Fachinformation zu Epoetin alfa, Warnhinweise und Vorsichtsmaßnahmen)

  • Atenolol und ChlortalidonBetablockerMittelschwer

    Following initiation and titration of Epogen, approximately 25% of patients on dialysis required initiation of or increases in antihypertensive therapy; hypertensive encephalopathy and seizures have been reported in patients with CKD receiving Epogen. (Fachinformation zu Epoetin alfa, Warnhinweise und Vorsichtsmaßnahmen)

  • AzilsartanAngiotensin-II-Rezeptorblocker (Sartan)Mittelschwer

    Following initiation and titration of Epogen, approximately 25% of patients on dialysis required initiation of or increases in antihypertensive therapy; hypertensive encephalopathy and seizures have been reported in patients with CKD receiving Epogen. (Fachinformation zu Epoetin alfa, Warnhinweise und Vorsichtsmaßnahmen)

  • BenazeprilACE-HemmerMittelschwer

    Following initiation and titration of Epogen, approximately 25% of patients on dialysis required initiation of or increases in antihypertensive therapy; hypertensive encephalopathy and seizures have been reported in patients with CKD receiving Epogen. (Fachinformation zu Epoetin alfa, Warnhinweise und Vorsichtsmaßnahmen)

  • Benazepril und HydrochlorothiazidACE-HemmerMittelschwer

    Following initiation and titration of Epogen, approximately 25% of patients on dialysis required initiation of or increases in antihypertensive therapy; hypertensive encephalopathy and seizures have been reported in patients with CKD receiving Epogen. (Fachinformation zu Epoetin alfa, Warnhinweise und Vorsichtsmaßnahmen)

  • BetaxololBetablockerMittelschwer

    Following initiation and titration of Epogen, approximately 25% of patients on dialysis required initiation of or increases in antihypertensive therapy; hypertensive encephalopathy and seizures have been reported in patients with CKD receiving Epogen. (Fachinformation zu Epoetin alfa, Warnhinweise und Vorsichtsmaßnahmen)

  • BisoprololBetablockerMittelschwer

    Following initiation and titration of Epogen, approximately 25% of patients on dialysis required initiation of or increases in antihypertensive therapy; hypertensive encephalopathy and seizures have been reported in patients with CKD receiving Epogen. (Fachinformation zu Epoetin alfa, Warnhinweise und Vorsichtsmaßnahmen)

  • Bisoprolol und HydrochlorothiazidBetablockerMittelschwer

    Following initiation and titration of Epogen, approximately 25% of patients on dialysis required initiation of or increases in antihypertensive therapy; hypertensive encephalopathy and seizures have been reported in patients with CKD receiving Epogen. (Fachinformation zu Epoetin alfa, Warnhinweise und Vorsichtsmaßnahmen)

  • CandesartanAngiotensin-II-Rezeptorblocker (Sartan)Mittelschwer

    Following initiation and titration of Epogen, approximately 25% of patients on dialysis required initiation of or increases in antihypertensive therapy; hypertensive encephalopathy and seizures have been reported in patients with CKD receiving Epogen. (Fachinformation zu Epoetin alfa, Warnhinweise und Vorsichtsmaßnahmen)

  • Candesartan und HydrochlorothiazidAngiotensin-II-Rezeptorblocker (Sartan)Mittelschwer

    Following initiation and titration of Epogen, approximately 25% of patients on dialysis required initiation of or increases in antihypertensive therapy; hypertensive encephalopathy and seizures have been reported in patients with CKD receiving Epogen. (Fachinformation zu Epoetin alfa, Warnhinweise und Vorsichtsmaßnahmen)

  • CaptoprilACE-HemmerMittelschwer

    Following initiation and titration of Epogen, approximately 25% of patients on dialysis required initiation of or increases in antihypertensive therapy; hypertensive encephalopathy and seizures have been reported in patients with CKD receiving Epogen. (Fachinformation zu Epoetin alfa, Warnhinweise und Vorsichtsmaßnahmen)

  • CarvedilolBetablockerMittelschwer

    Following initiation and titration of Epogen, approximately 25% of patients on dialysis required initiation of or increases in antihypertensive therapy; hypertensive encephalopathy and seizures have been reported in patients with CKD receiving Epogen. (Fachinformation zu Epoetin alfa, Warnhinweise und Vorsichtsmaßnahmen)

  • ChlorothiazidThiaziddiuretikumMittelschwer

    Following initiation and titration of Epogen, approximately 25% of patients on dialysis required initiation of or increases in antihypertensive therapy; hypertensive encephalopathy and seizures have been reported in patients with CKD receiving Epogen. (Fachinformation zu Epoetin alfa, Warnhinweise und Vorsichtsmaßnahmen)

  • ChlortalidonThiaziddiuretikumMittelschwer

    Following initiation and titration of Epogen, approximately 25% of patients on dialysis required initiation of or increases in antihypertensive therapy; hypertensive encephalopathy and seizures have been reported in patients with CKD receiving Epogen. (Fachinformation zu Epoetin alfa, Warnhinweise und Vorsichtsmaßnahmen)

  • ClonidinAlpha-Adrenozeptor-AgonistMittelschwer

    Following initiation and titration of Epogen, approximately 25% of patients on dialysis required initiation of or increases in antihypertensive therapy; hypertensive encephalopathy and seizures have been reported in patients with CKD receiving Epogen. (Fachinformation zu Epoetin alfa, Warnhinweise und Vorsichtsmaßnahmen)

  • DiltiazemCalciumkanalblockerMittelschwer

    Following initiation and titration of Epogen, approximately 25% of patients on dialysis required initiation of or increases in antihypertensive therapy; hypertensive encephalopathy and seizures have been reported in patients with CKD receiving Epogen. (Fachinformation zu Epoetin alfa, Warnhinweise und Vorsichtsmaßnahmen)

  • DoxazosinAlphablockerMittelschwer

    Following initiation and titration of Epogen, approximately 25% of patients on dialysis required initiation of or increases in antihypertensive therapy; hypertensive encephalopathy and seizures have been reported in patients with CKD receiving Epogen. (Fachinformation zu Epoetin alfa, Warnhinweise und Vorsichtsmaßnahmen)

  • EnalaprilACE-HemmerMittelschwer

    Following initiation and titration of Epogen, approximately 25% of patients on dialysis required initiation of or increases in antihypertensive therapy; hypertensive encephalopathy and seizures have been reported in patients with CKD receiving Epogen. (Fachinformation zu Epoetin alfa, Warnhinweise und Vorsichtsmaßnahmen)

  • Enalapril und HydrochlorothiazidACE-HemmerMittelschwer

    Following initiation and titration of Epogen, approximately 25% of patients on dialysis required initiation of or increases in antihypertensive therapy; hypertensive encephalopathy and seizures have been reported in patients with CKD receiving Epogen. (Fachinformation zu Epoetin alfa, Warnhinweise und Vorsichtsmaßnahmen)

  • EnalaprilatACE-HemmerMittelschwer

    Following initiation and titration of Epogen, approximately 25% of patients on dialysis required initiation of or increases in antihypertensive therapy; hypertensive encephalopathy and seizures have been reported in patients with CKD receiving Epogen. (Fachinformation zu Epoetin alfa, Warnhinweise und Vorsichtsmaßnahmen)

  • EnoxaparinAntikoagulans (Gerinnungshemmer)Mittelschwer

    Patients receiving Epogen may require increased anticoagulation with heparin to prevent clotting of the extracorporeal circuit during hemodialysis. (Fachinformation zu Epoetin alfa, Warnhinweise und Vorsichtsmaßnahmen)

  • EplerenonAldosteronantagonistMittelschwer

    Following initiation and titration of Epogen, approximately 25% of patients on dialysis required initiation of or increases in antihypertensive therapy; hypertensive encephalopathy and seizures have been reported in patients with CKD receiving Epogen. (Fachinformation zu Epoetin alfa, Warnhinweise und Vorsichtsmaßnahmen)

  • EtacrynsäureSchleifendiuretikumMittelschwer

    Following initiation and titration of Epogen, approximately 25% of patients on dialysis required initiation of or increases in antihypertensive therapy; hypertensive encephalopathy and seizures have been reported in patients with CKD receiving Epogen. (Fachinformation zu Epoetin alfa, Warnhinweise und Vorsichtsmaßnahmen)

  • FelodipinDihydropyridin-CalciumkanalblockerMittelschwer

    Following initiation and titration of Epogen, approximately 25% of patients on dialysis required initiation of or increases in antihypertensive therapy; hypertensive encephalopathy and seizures have been reported in patients with CKD receiving Epogen. (Fachinformation zu Epoetin alfa, Warnhinweise und Vorsichtsmaßnahmen)

  • FosinoprilACE-HemmerMittelschwer

    Following initiation and titration of Epogen, approximately 25% of patients on dialysis required initiation of or increases in antihypertensive therapy; hypertensive encephalopathy and seizures have been reported in patients with CKD receiving Epogen. (Fachinformation zu Epoetin alfa, Warnhinweise und Vorsichtsmaßnahmen)

  • Fosinopril und HydrochlorothiazidACE-HemmerMittelschwer

    Following initiation and titration of Epogen, approximately 25% of patients on dialysis required initiation of or increases in antihypertensive therapy; hypertensive encephalopathy and seizures have been reported in patients with CKD receiving Epogen. (Fachinformation zu Epoetin alfa, Warnhinweise und Vorsichtsmaßnahmen)

  • FurosemidSchleifendiuretikumMittelschwer

    Following initiation and titration of Epogen, approximately 25% of patients on dialysis required initiation of or increases in antihypertensive therapy; hypertensive encephalopathy and seizures have been reported in patients with CKD receiving Epogen. (Fachinformation zu Epoetin alfa, Warnhinweise und Vorsichtsmaßnahmen)

  • GuanfacinAlpha-Adrenozeptor-AgonistMittelschwer

    Following initiation and titration of Epogen, approximately 25% of patients on dialysis required initiation of or increases in antihypertensive therapy; hypertensive encephalopathy and seizures have been reported in patients with CKD receiving Epogen. (Fachinformation zu Epoetin alfa, Warnhinweise und Vorsichtsmaßnahmen)

  • HeparinAntikoagulans (Gerinnungshemmer)Mittelschwer

    Patients receiving Epogen may require increased anticoagulation with heparin to prevent clotting of the extracorporeal circuit during hemodialysis. (Fachinformation zu Epoetin alfa, Warnhinweise und Vorsichtsmaßnahmen)

  • HydralazinVasodilatatorMittelschwer

    Following initiation and titration of Epogen, approximately 25% of patients on dialysis required initiation of or increases in antihypertensive therapy; hypertensive encephalopathy and seizures have been reported in patients with CKD receiving Epogen. (Fachinformation zu Epoetin alfa, Warnhinweise und Vorsichtsmaßnahmen)

  • HydrochlorothiazidThiaziddiuretikumMittelschwer

    Following initiation and titration of Epogen, approximately 25% of patients on dialysis required initiation of or increases in antihypertensive therapy; hypertensive encephalopathy and seizures have been reported in patients with CKD receiving Epogen. (Fachinformation zu Epoetin alfa, Warnhinweise und Vorsichtsmaßnahmen)

  • IndapamidThiaziddiuretikumMittelschwer

    Following initiation and titration of Epogen, approximately 25% of patients on dialysis required initiation of or increases in antihypertensive therapy; hypertensive encephalopathy and seizures have been reported in patients with CKD receiving Epogen. (Fachinformation zu Epoetin alfa, Warnhinweise und Vorsichtsmaßnahmen)

  • IrbesartanAngiotensin-II-Rezeptorblocker (Sartan)Mittelschwer

    Following initiation and titration of Epogen, approximately 25% of patients on dialysis required initiation of or increases in antihypertensive therapy; hypertensive encephalopathy and seizures have been reported in patients with CKD receiving Epogen. (Fachinformation zu Epoetin alfa, Warnhinweise und Vorsichtsmaßnahmen)

  • Irbesartan und HydrochlorothiazidAngiotensin-II-Rezeptorblocker (Sartan)Mittelschwer

    Following initiation and titration of Epogen, approximately 25% of patients on dialysis required initiation of or increases in antihypertensive therapy; hypertensive encephalopathy and seizures have been reported in patients with CKD receiving Epogen. (Fachinformation zu Epoetin alfa, Warnhinweise und Vorsichtsmaßnahmen)

  • Isosorbiddinitrat und HydralazinNitratMittelschwer

    Following initiation and titration of Epogen, approximately 25% of patients on dialysis required initiation of or increases in antihypertensive therapy; hypertensive encephalopathy and seizures have been reported in patients with CKD receiving Epogen. (Fachinformation zu Epoetin alfa, Warnhinweise und Vorsichtsmaßnahmen)

  • IsradipinDihydropyridin-CalciumkanalblockerMittelschwer

    Following initiation and titration of Epogen, approximately 25% of patients on dialysis required initiation of or increases in antihypertensive therapy; hypertensive encephalopathy and seizures have been reported in patients with CKD receiving Epogen. (Fachinformation zu Epoetin alfa, Warnhinweise und Vorsichtsmaßnahmen)

  • LabetalolBetablockerMittelschwer

    Following initiation and titration of Epogen, approximately 25% of patients on dialysis required initiation of or increases in antihypertensive therapy; hypertensive encephalopathy and seizures have been reported in patients with CKD receiving Epogen. (Fachinformation zu Epoetin alfa, Warnhinweise und Vorsichtsmaßnahmen)

  • LisinoprilACE-HemmerMittelschwer

    Following initiation and titration of Epogen, approximately 25% of patients on dialysis required initiation of or increases in antihypertensive therapy; hypertensive encephalopathy and seizures have been reported in patients with CKD receiving Epogen. (Fachinformation zu Epoetin alfa, Warnhinweise und Vorsichtsmaßnahmen)

  • Lisinopril und HydrochlorothiazidACE-HemmerMittelschwer

    Following initiation and titration of Epogen, approximately 25% of patients on dialysis required initiation of or increases in antihypertensive therapy; hypertensive encephalopathy and seizures have been reported in patients with CKD receiving Epogen. (Fachinformation zu Epoetin alfa, Warnhinweise und Vorsichtsmaßnahmen)

  • LofexidinAlpha-Adrenozeptor-AgonistMittelschwer

    Following initiation and titration of Epogen, approximately 25% of patients on dialysis required initiation of or increases in antihypertensive therapy; hypertensive encephalopathy and seizures have been reported in patients with CKD receiving Epogen. (Fachinformation zu Epoetin alfa, Warnhinweise und Vorsichtsmaßnahmen)

  • LosartanAngiotensin-II-Rezeptorblocker (Sartan)Mittelschwer

    Following initiation and titration of Epogen, approximately 25% of patients on dialysis required initiation of or increases in antihypertensive therapy; hypertensive encephalopathy and seizures have been reported in patients with CKD receiving Epogen. (Fachinformation zu Epoetin alfa, Warnhinweise und Vorsichtsmaßnahmen)

  • Losartan und HydrochlorothiazidAngiotensin-II-Rezeptorblocker (Sartan)Mittelschwer

    Following initiation and titration of Epogen, approximately 25% of patients on dialysis required initiation of or increases in antihypertensive therapy; hypertensive encephalopathy and seizures have been reported in patients with CKD receiving Epogen. (Fachinformation zu Epoetin alfa, Warnhinweise und Vorsichtsmaßnahmen)

  • MecamylaminAntihypertensivumMittelschwer

    Following initiation and titration of Epogen, approximately 25% of patients on dialysis required initiation of or increases in antihypertensive therapy; hypertensive encephalopathy and seizures have been reported in patients with CKD receiving Epogen. (Fachinformation zu Epoetin alfa, Warnhinweise und Vorsichtsmaßnahmen)

  • MethyldopaAntihypertensivumMittelschwer

    Following initiation and titration of Epogen, approximately 25% of patients on dialysis required initiation of or increases in antihypertensive therapy; hypertensive encephalopathy and seizures have been reported in patients with CKD receiving Epogen. (Fachinformation zu Epoetin alfa, Warnhinweise und Vorsichtsmaßnahmen)

  • MetolazonThiaziddiuretikumMittelschwer

    Following initiation and titration of Epogen, approximately 25% of patients on dialysis required initiation of or increases in antihypertensive therapy; hypertensive encephalopathy and seizures have been reported in patients with CKD receiving Epogen. (Fachinformation zu Epoetin alfa, Warnhinweise und Vorsichtsmaßnahmen)

  • MetoprololBetablockerMittelschwer

    Following initiation and titration of Epogen, approximately 25% of patients on dialysis required initiation of or increases in antihypertensive therapy; hypertensive encephalopathy and seizures have been reported in patients with CKD receiving Epogen. (Fachinformation zu Epoetin alfa, Warnhinweise und Vorsichtsmaßnahmen)

  • Metoprolol und HydrochlorothiazidBetablockerMittelschwer

    Following initiation and titration of Epogen, approximately 25% of patients on dialysis required initiation of or increases in antihypertensive therapy; hypertensive encephalopathy and seizures have been reported in patients with CKD receiving Epogen. (Fachinformation zu Epoetin alfa, Warnhinweise und Vorsichtsmaßnahmen)

  • MinoxidilVasodilatatorMittelschwer

    Following initiation and titration of Epogen, approximately 25% of patients on dialysis required initiation of or increases in antihypertensive therapy; hypertensive encephalopathy and seizures have been reported in patients with CKD receiving Epogen. (Fachinformation zu Epoetin alfa, Warnhinweise und Vorsichtsmaßnahmen)

  • MoexiprilACE-HemmerMittelschwer

    Following initiation and titration of Epogen, approximately 25% of patients on dialysis required initiation of or increases in antihypertensive therapy; hypertensive encephalopathy and seizures have been reported in patients with CKD receiving Epogen. (Fachinformation zu Epoetin alfa, Warnhinweise und Vorsichtsmaßnahmen)

  • NadololBetablockerMittelschwer

    Following initiation and titration of Epogen, approximately 25% of patients on dialysis required initiation of or increases in antihypertensive therapy; hypertensive encephalopathy and seizures have been reported in patients with CKD receiving Epogen. (Fachinformation zu Epoetin alfa, Warnhinweise und Vorsichtsmaßnahmen)

  • NebivololBetablockerMittelschwer

    Following initiation and titration of Epogen, approximately 25% of patients on dialysis required initiation of or increases in antihypertensive therapy; hypertensive encephalopathy and seizures have been reported in patients with CKD receiving Epogen. (Fachinformation zu Epoetin alfa, Warnhinweise und Vorsichtsmaßnahmen)

  • NicardipinDihydropyridin-CalciumkanalblockerMittelschwer

    Following initiation and titration of Epogen, approximately 25% of patients on dialysis required initiation of or increases in antihypertensive therapy; hypertensive encephalopathy and seizures have been reported in patients with CKD receiving Epogen. (Fachinformation zu Epoetin alfa, Warnhinweise und Vorsichtsmaßnahmen)

  • NifedipinDihydropyridin-CalciumkanalblockerMittelschwer

    Following initiation and titration of Epogen, approximately 25% of patients on dialysis required initiation of or increases in antihypertensive therapy; hypertensive encephalopathy and seizures have been reported in patients with CKD receiving Epogen. (Fachinformation zu Epoetin alfa, Warnhinweise und Vorsichtsmaßnahmen)

  • NisoldipinDihydropyridin-CalciumkanalblockerMittelschwer

    Following initiation and titration of Epogen, approximately 25% of patients on dialysis required initiation of or increases in antihypertensive therapy; hypertensive encephalopathy and seizures have been reported in patients with CKD receiving Epogen. (Fachinformation zu Epoetin alfa, Warnhinweise und Vorsichtsmaßnahmen)

  • NitroprussidnatriumVasodilatatorMittelschwer

    Following initiation and titration of Epogen, approximately 25% of patients on dialysis required initiation of or increases in antihypertensive therapy; hypertensive encephalopathy and seizures have been reported in patients with CKD receiving Epogen. (Fachinformation zu Epoetin alfa, Warnhinweise und Vorsichtsmaßnahmen)

  • OlmesartanAngiotensin-II-Rezeptorblocker (Sartan)Mittelschwer

    Following initiation and titration of Epogen, approximately 25% of patients on dialysis required initiation of or increases in antihypertensive therapy; hypertensive encephalopathy and seizures have been reported in patients with CKD receiving Epogen. (Fachinformation zu Epoetin alfa, Warnhinweise und Vorsichtsmaßnahmen)

  • Olmesartan und HydrochlorothiazidAngiotensin-II-Rezeptorblocker (Sartan)Mittelschwer

    Following initiation and titration of Epogen, approximately 25% of patients on dialysis required initiation of or increases in antihypertensive therapy; hypertensive encephalopathy and seizures have been reported in patients with CKD receiving Epogen. (Fachinformation zu Epoetin alfa, Warnhinweise und Vorsichtsmaßnahmen)

  • Olmesartan, Amlodipin und HydrochlorothiazidAngiotensin-II-Rezeptorblocker (Sartan)Mittelschwer

    Following initiation and titration of Epogen, approximately 25% of patients on dialysis required initiation of or increases in antihypertensive therapy; hypertensive encephalopathy and seizures have been reported in patients with CKD receiving Epogen. (Fachinformation zu Epoetin alfa, Warnhinweise und Vorsichtsmaßnahmen)

  • PerindoprilACE-HemmerMittelschwer

    Following initiation and titration of Epogen, approximately 25% of patients on dialysis required initiation of or increases in antihypertensive therapy; hypertensive encephalopathy and seizures have been reported in patients with CKD receiving Epogen. (Fachinformation zu Epoetin alfa, Warnhinweise und Vorsichtsmaßnahmen)

  • PhenoxybenzaminAlphablockerMittelschwer

    Following initiation and titration of Epogen, approximately 25% of patients on dialysis required initiation of or increases in antihypertensive therapy; hypertensive encephalopathy and seizures have been reported in patients with CKD receiving Epogen. (Fachinformation zu Epoetin alfa, Warnhinweise und Vorsichtsmaßnahmen)

  • PindololBetablockerMittelschwer

    Following initiation and titration of Epogen, approximately 25% of patients on dialysis required initiation of or increases in antihypertensive therapy; hypertensive encephalopathy and seizures have been reported in patients with CKD receiving Epogen. (Fachinformation zu Epoetin alfa, Warnhinweise und Vorsichtsmaßnahmen)

  • PrazosinAlphablockerMittelschwer

    Following initiation and titration of Epogen, approximately 25% of patients on dialysis required initiation of or increases in antihypertensive therapy; hypertensive encephalopathy and seizures have been reported in patients with CKD receiving Epogen. (Fachinformation zu Epoetin alfa, Warnhinweise und Vorsichtsmaßnahmen)

  • PropranololBetablockerMittelschwer

    Following initiation and titration of Epogen, approximately 25% of patients on dialysis required initiation of or increases in antihypertensive therapy; hypertensive encephalopathy and seizures have been reported in patients with CKD receiving Epogen. (Fachinformation zu Epoetin alfa, Warnhinweise und Vorsichtsmaßnahmen)

  • QuinaprilACE-HemmerMittelschwer

    Following initiation and titration of Epogen, approximately 25% of patients on dialysis required initiation of or increases in antihypertensive therapy; hypertensive encephalopathy and seizures have been reported in patients with CKD receiving Epogen. (Fachinformation zu Epoetin alfa, Warnhinweise und Vorsichtsmaßnahmen)

  • Quinapril und HydrochlorothiazidACE-HemmerMittelschwer

    Following initiation and titration of Epogen, approximately 25% of patients on dialysis required initiation of or increases in antihypertensive therapy; hypertensive encephalopathy and seizures have been reported in patients with CKD receiving Epogen. (Fachinformation zu Epoetin alfa, Warnhinweise und Vorsichtsmaßnahmen)

  • RamiprilACE-HemmerMittelschwer

    Following initiation and titration of Epogen, approximately 25% of patients on dialysis required initiation of or increases in antihypertensive therapy; hypertensive encephalopathy and seizures have been reported in patients with CKD receiving Epogen. (Fachinformation zu Epoetin alfa, Warnhinweise und Vorsichtsmaßnahmen)

  • Sacubitril und ValsartanAngiotensin-II-Rezeptorblocker (Sartan)Mittelschwer

    Following initiation and titration of Epogen, approximately 25% of patients on dialysis required initiation of or increases in antihypertensive therapy; hypertensive encephalopathy and seizures have been reported in patients with CKD receiving Epogen. (Fachinformation zu Epoetin alfa, Warnhinweise und Vorsichtsmaßnahmen)

  • SpironolactonAldosteronantagonistMittelschwer

    Following initiation and titration of Epogen, approximately 25% of patients on dialysis required initiation of or increases in antihypertensive therapy; hypertensive encephalopathy and seizures have been reported in patients with CKD receiving Epogen. (Fachinformation zu Epoetin alfa, Warnhinweise und Vorsichtsmaßnahmen)

  • Spironolacton und HydrochlorothiazidAldosteronantagonistMittelschwer

    Following initiation and titration of Epogen, approximately 25% of patients on dialysis required initiation of or increases in antihypertensive therapy; hypertensive encephalopathy and seizures have been reported in patients with CKD receiving Epogen. (Fachinformation zu Epoetin alfa, Warnhinweise und Vorsichtsmaßnahmen)

  • TelmisartanAngiotensin-II-Rezeptorblocker (Sartan)Mittelschwer

    Following initiation and titration of Epogen, approximately 25% of patients on dialysis required initiation of or increases in antihypertensive therapy; hypertensive encephalopathy and seizures have been reported in patients with CKD receiving Epogen. (Fachinformation zu Epoetin alfa, Warnhinweise und Vorsichtsmaßnahmen)

  • Telmisartan und AmlodipinAngiotensin-II-Rezeptorblocker (Sartan)Mittelschwer

    Following initiation and titration of Epogen, approximately 25% of patients on dialysis required initiation of or increases in antihypertensive therapy; hypertensive encephalopathy and seizures have been reported in patients with CKD receiving Epogen. (Fachinformation zu Epoetin alfa, Warnhinweise und Vorsichtsmaßnahmen)

  • Telmisartan und HydrochlorothiazidAngiotensin-II-Rezeptorblocker (Sartan)Mittelschwer

    Following initiation and titration of Epogen, approximately 25% of patients on dialysis required initiation of or increases in antihypertensive therapy; hypertensive encephalopathy and seizures have been reported in patients with CKD receiving Epogen. (Fachinformation zu Epoetin alfa, Warnhinweise und Vorsichtsmaßnahmen)

  • TerazosinAlphablockerMittelschwer

    Following initiation and titration of Epogen, approximately 25% of patients on dialysis required initiation of or increases in antihypertensive therapy; hypertensive encephalopathy and seizures have been reported in patients with CKD receiving Epogen. (Fachinformation zu Epoetin alfa, Warnhinweise und Vorsichtsmaßnahmen)

  • TizanidinMuskelrelaxansMittelschwer

    Following initiation and titration of Epogen, approximately 25% of patients on dialysis required initiation of or increases in antihypertensive therapy; hypertensive encephalopathy and seizures have been reported in patients with CKD receiving Epogen. (Fachinformation zu Epoetin alfa, Warnhinweise und Vorsichtsmaßnahmen)

  • TorasemidSchleifendiuretikumMittelschwer

    Following initiation and titration of Epogen, approximately 25% of patients on dialysis required initiation of or increases in antihypertensive therapy; hypertensive encephalopathy and seizures have been reported in patients with CKD receiving Epogen. (Fachinformation zu Epoetin alfa, Warnhinweise und Vorsichtsmaßnahmen)

  • TrandolaprilACE-HemmerMittelschwer

    Following initiation and titration of Epogen, approximately 25% of patients on dialysis required initiation of or increases in antihypertensive therapy; hypertensive encephalopathy and seizures have been reported in patients with CKD receiving Epogen. (Fachinformation zu Epoetin alfa, Warnhinweise und Vorsichtsmaßnahmen)

  • Triamterenkaliumsparendes DiuretikumMittelschwer

    Following initiation and titration of Epogen, approximately 25% of patients on dialysis required initiation of or increases in antihypertensive therapy; hypertensive encephalopathy and seizures have been reported in patients with CKD receiving Epogen. (Fachinformation zu Epoetin alfa, Warnhinweise und Vorsichtsmaßnahmen)

  • Triamteren und Hydrochlorothiazidkaliumsparendes DiuretikumMittelschwer

    Following initiation and titration of Epogen, approximately 25% of patients on dialysis required initiation of or increases in antihypertensive therapy; hypertensive encephalopathy and seizures have been reported in patients with CKD receiving Epogen. (Fachinformation zu Epoetin alfa, Warnhinweise und Vorsichtsmaßnahmen)

  • ValsartanAngiotensin-II-Rezeptorblocker (Sartan)Mittelschwer

    Following initiation and titration of Epogen, approximately 25% of patients on dialysis required initiation of or increases in antihypertensive therapy; hypertensive encephalopathy and seizures have been reported in patients with CKD receiving Epogen. (Fachinformation zu Epoetin alfa, Warnhinweise und Vorsichtsmaßnahmen)

  • Valsartan und HydrochlorothiazidAngiotensin-II-Rezeptorblocker (Sartan)Mittelschwer

    Following initiation and titration of Epogen, approximately 25% of patients on dialysis required initiation of or increases in antihypertensive therapy; hypertensive encephalopathy and seizures have been reported in patients with CKD receiving Epogen. (Fachinformation zu Epoetin alfa, Warnhinweise und Vorsichtsmaßnahmen)

  • VerapamilCalciumkanalblockerMittelschwer

    Following initiation and titration of Epogen, approximately 25% of patients on dialysis required initiation of or increases in antihypertensive therapy; hypertensive encephalopathy and seizures have been reported in patients with CKD receiving Epogen. (Fachinformation zu Epoetin alfa, Warnhinweise und Vorsichtsmaßnahmen)

Geringfügige Erwähnungen (159)

  • AlprazolamBenzodiazepinGeringfügig

    The “gasping syndrome” is characterized by central nervous system (CNS) depression, metabolic acidosis, and gasping respirations. (Fachinformation zu Epoetin alfa, Warnhinweise und Vorsichtsmaßnahmen)

  • Amitriptylintrizyklisches AntidepressivumGeringfügig

    The “gasping syndrome” is characterized by central nervous system (CNS) depression, metabolic acidosis, and gasping respirations. (Fachinformation zu Epoetin alfa, Warnhinweise und Vorsichtsmaßnahmen)

  • Amoxapintrizyklisches AntidepressivumGeringfügig

    The “gasping syndrome” is characterized by central nervous system (CNS) depression, metabolic acidosis, and gasping respirations. (Fachinformation zu Epoetin alfa, Warnhinweise und Vorsichtsmaßnahmen)

  • AripiprazolAntipsychotikumGeringfügig

    The “gasping syndrome” is characterized by central nervous system (CNS) depression, metabolic acidosis, and gasping respirations. (Fachinformation zu Epoetin alfa, Warnhinweise und Vorsichtsmaßnahmen)

  • AsenapinAntipsychotikumGeringfügig

    The “gasping syndrome” is characterized by central nervous system (CNS) depression, metabolic acidosis, and gasping respirations. (Fachinformation zu Epoetin alfa, Warnhinweise und Vorsichtsmaßnahmen)

  • AzelastinAntihistaminikumGeringfügig

    The “gasping syndrome” is characterized by central nervous system (CNS) depression, metabolic acidosis, and gasping respirations. (Fachinformation zu Epoetin alfa, Warnhinweise und Vorsichtsmaßnahmen)

  • Azelastin und FluticasonAntihistaminikumGeringfügig

    The “gasping syndrome” is characterized by central nervous system (CNS) depression, metabolic acidosis, and gasping respirations. (Fachinformation zu Epoetin alfa, Warnhinweise und Vorsichtsmaßnahmen)

  • BaclofenMuskelrelaxansGeringfügig

    The “gasping syndrome” is characterized by central nervous system (CNS) depression, metabolic acidosis, and gasping respirations. (Fachinformation zu Epoetin alfa, Warnhinweise und Vorsichtsmaßnahmen)

  • Belladonna und OpiumOpioidGeringfügig

    The “gasping syndrome” is characterized by central nervous system (CNS) depression, metabolic acidosis, and gasping respirations. (Fachinformation zu Epoetin alfa, Warnhinweise und Vorsichtsmaßnahmen)

  • BrexpiprazolAntipsychotikumGeringfügig

    The “gasping syndrome” is characterized by central nervous system (CNS) depression, metabolic acidosis, and gasping respirations. (Fachinformation zu Epoetin alfa, Warnhinweise und Vorsichtsmaßnahmen)

  • BrivaracetamAntiepileptikumGeringfügig

    The “gasping syndrome” is characterized by central nervous system (CNS) depression, metabolic acidosis, and gasping respirations. (Fachinformation zu Epoetin alfa, Warnhinweise und Vorsichtsmaßnahmen)

  • Brompheniramin, Pseudoephedrin und DextromethorphanAntihistaminikumGeringfügig

    The “gasping syndrome” is characterized by central nervous system (CNS) depression, metabolic acidosis, and gasping respirations. (Fachinformation zu Epoetin alfa, Warnhinweise und Vorsichtsmaßnahmen)

  • BuprenorphinOpioidGeringfügig

    The “gasping syndrome” is characterized by central nervous system (CNS) depression, metabolic acidosis, and gasping respirations. (Fachinformation zu Epoetin alfa, Warnhinweise und Vorsichtsmaßnahmen)

  • Buprenorphin und NaloxonOpioidGeringfügig

    The “gasping syndrome” is characterized by central nervous system (CNS) depression, metabolic acidosis, and gasping respirations. (Fachinformation zu Epoetin alfa, Warnhinweise und Vorsichtsmaßnahmen)

  • Butalbital und ParacetamolBarbituratGeringfügig

    The “gasping syndrome” is characterized by central nervous system (CNS) depression, metabolic acidosis, and gasping respirations. (Fachinformation zu Epoetin alfa, Warnhinweise und Vorsichtsmaßnahmen)

  • Butalbital, Acetylsalicylsäure und KoffeinBarbituratGeringfügig

    The “gasping syndrome” is characterized by central nervous system (CNS) depression, metabolic acidosis, and gasping respirations. (Fachinformation zu Epoetin alfa, Warnhinweise und Vorsichtsmaßnahmen)

  • Butalbital, Acetylsalicylsäure, Koffein und CodeinBarbituratGeringfügig

    The “gasping syndrome” is characterized by central nervous system (CNS) depression, metabolic acidosis, and gasping respirations. (Fachinformation zu Epoetin alfa, Warnhinweise und Vorsichtsmaßnahmen)

  • Butalbital, Paracetamol und KoffeinBarbituratGeringfügig

    The “gasping syndrome” is characterized by central nervous system (CNS) depression, metabolic acidosis, and gasping respirations. (Fachinformation zu Epoetin alfa, Warnhinweise und Vorsichtsmaßnahmen)

  • Butalbital, Paracetamol, Koffein und CodeinBarbituratGeringfügig

    The “gasping syndrome” is characterized by central nervous system (CNS) depression, metabolic acidosis, and gasping respirations. (Fachinformation zu Epoetin alfa, Warnhinweise und Vorsichtsmaßnahmen)

  • ButorphanolOpioidGeringfügig

    The “gasping syndrome” is characterized by central nervous system (CNS) depression, metabolic acidosis, and gasping respirations. (Fachinformation zu Epoetin alfa, Warnhinweise und Vorsichtsmaßnahmen)

  • Cannabidiol (verschreibungspflichtig)AntiepileptikumGeringfügig

    The “gasping syndrome” is characterized by central nervous system (CNS) depression, metabolic acidosis, and gasping respirations. (Fachinformation zu Epoetin alfa, Warnhinweise und Vorsichtsmaßnahmen)

  • CarbamazepinAntiepileptikumGeringfügig

    The “gasping syndrome” is characterized by central nervous system (CNS) depression, metabolic acidosis, and gasping respirations. (Fachinformation zu Epoetin alfa, Warnhinweise und Vorsichtsmaßnahmen)

  • CarbinoxaminAntihistaminikumGeringfügig

    The “gasping syndrome” is characterized by central nervous system (CNS) depression, metabolic acidosis, and gasping respirations. (Fachinformation zu Epoetin alfa, Warnhinweise und Vorsichtsmaßnahmen)

  • CariprazinAntipsychotikumGeringfügig

    The “gasping syndrome” is characterized by central nervous system (CNS) depression, metabolic acidosis, and gasping respirations. (Fachinformation zu Epoetin alfa, Warnhinweise und Vorsichtsmaßnahmen)

  • CarisoprodolMuskelrelaxansGeringfügig

    The “gasping syndrome” is characterized by central nervous system (CNS) depression, metabolic acidosis, and gasping respirations. (Fachinformation zu Epoetin alfa, Warnhinweise und Vorsichtsmaßnahmen)

  • CenobamatAntiepileptikumGeringfügig

    The “gasping syndrome” is characterized by central nervous system (CNS) depression, metabolic acidosis, and gasping respirations. (Fachinformation zu Epoetin alfa, Warnhinweise und Vorsichtsmaßnahmen)

  • ChlordiazepoxidBenzodiazepinGeringfügig

    The “gasping syndrome” is characterized by central nervous system (CNS) depression, metabolic acidosis, and gasping respirations. (Fachinformation zu Epoetin alfa, Warnhinweise und Vorsichtsmaßnahmen)

  • Chlordiazepoxid und ClidiniumbromidBenzodiazepinGeringfügig

    The “gasping syndrome” is characterized by central nervous system (CNS) depression, metabolic acidosis, and gasping respirations. (Fachinformation zu Epoetin alfa, Warnhinweise und Vorsichtsmaßnahmen)

  • ChlorphenaminAntihistaminikumGeringfügig

    The “gasping syndrome” is characterized by central nervous system (CNS) depression, metabolic acidosis, and gasping respirations. (Fachinformation zu Epoetin alfa, Warnhinweise und Vorsichtsmaßnahmen)

  • ChlorpromazinAntipsychotikumGeringfügig

    The “gasping syndrome” is characterized by central nervous system (CNS) depression, metabolic acidosis, and gasping respirations. (Fachinformation zu Epoetin alfa, Warnhinweise und Vorsichtsmaßnahmen)

  • ChlorzoxazonMuskelrelaxansGeringfügig

    The “gasping syndrome” is characterized by central nervous system (CNS) depression, metabolic acidosis, and gasping respirations. (Fachinformation zu Epoetin alfa, Warnhinweise und Vorsichtsmaßnahmen)

  • ClemastinAntihistaminikumGeringfügig

    The “gasping syndrome” is characterized by central nervous system (CNS) depression, metabolic acidosis, and gasping respirations. (Fachinformation zu Epoetin alfa, Warnhinweise und Vorsichtsmaßnahmen)

  • ClobazamBenzodiazepinGeringfügig

    The “gasping syndrome” is characterized by central nervous system (CNS) depression, metabolic acidosis, and gasping respirations. (Fachinformation zu Epoetin alfa, Warnhinweise und Vorsichtsmaßnahmen)

  • Clomipramintrizyklisches AntidepressivumGeringfügig

    The “gasping syndrome” is characterized by central nervous system (CNS) depression, metabolic acidosis, and gasping respirations. (Fachinformation zu Epoetin alfa, Warnhinweise und Vorsichtsmaßnahmen)

  • ClonazepamBenzodiazepinGeringfügig

    The “gasping syndrome” is characterized by central nervous system (CNS) depression, metabolic acidosis, and gasping respirations. (Fachinformation zu Epoetin alfa, Warnhinweise und Vorsichtsmaßnahmen)

  • ClozapinAntipsychotikumGeringfügig

    The “gasping syndrome” is characterized by central nervous system (CNS) depression, metabolic acidosis, and gasping respirations. (Fachinformation zu Epoetin alfa, Warnhinweise und Vorsichtsmaßnahmen)

  • CodeinOpioidGeringfügig

    The “gasping syndrome” is characterized by central nervous system (CNS) depression, metabolic acidosis, and gasping respirations. (Fachinformation zu Epoetin alfa, Warnhinweise und Vorsichtsmaßnahmen)

  • CyclobenzaprinMuskelrelaxansGeringfügig

    The “gasping syndrome” is characterized by central nervous system (CNS) depression, metabolic acidosis, and gasping respirations. (Fachinformation zu Epoetin alfa, Warnhinweise und Vorsichtsmaßnahmen)

  • CyproheptadinAntihistaminikumGeringfügig

    The “gasping syndrome” is characterized by central nervous system (CNS) depression, metabolic acidosis, and gasping respirations. (Fachinformation zu Epoetin alfa, Warnhinweise und Vorsichtsmaßnahmen)

  • DantrolenMuskelrelaxansGeringfügig

    The “gasping syndrome” is characterized by central nervous system (CNS) depression, metabolic acidosis, and gasping respirations. (Fachinformation zu Epoetin alfa, Warnhinweise und Vorsichtsmaßnahmen)

  • DaridorexantSchlaf- und BeruhigungsmittelGeringfügig

    The “gasping syndrome” is characterized by central nervous system (CNS) depression, metabolic acidosis, and gasping respirations. (Fachinformation zu Epoetin alfa, Warnhinweise und Vorsichtsmaßnahmen)

  • DesfluranAllgemeinanästhetikumGeringfügig

    The “gasping syndrome” is characterized by central nervous system (CNS) depression, metabolic acidosis, and gasping respirations. (Fachinformation zu Epoetin alfa, Warnhinweise und Vorsichtsmaßnahmen)

  • Desipramintrizyklisches AntidepressivumGeringfügig

    The “gasping syndrome” is characterized by central nervous system (CNS) depression, metabolic acidosis, and gasping respirations. (Fachinformation zu Epoetin alfa, Warnhinweise und Vorsichtsmaßnahmen)

  • DexchlorpheniraminAntihistaminikumGeringfügig

    The “gasping syndrome” is characterized by central nervous system (CNS) depression, metabolic acidosis, and gasping respirations. (Fachinformation zu Epoetin alfa, Warnhinweise und Vorsichtsmaßnahmen)

  • DexmedetomidinAlpha-Adrenozeptor-AgonistGeringfügig

    The “gasping syndrome” is characterized by central nervous system (CNS) depression, metabolic acidosis, and gasping respirations. (Fachinformation zu Epoetin alfa, Warnhinweise und Vorsichtsmaßnahmen)

  • DiazepamBenzodiazepinGeringfügig

    The “gasping syndrome” is characterized by central nervous system (CNS) depression, metabolic acidosis, and gasping respirations. (Fachinformation zu Epoetin alfa, Warnhinweise und Vorsichtsmaßnahmen)

  • DikaliumclorazepatBenzodiazepinGeringfügig

    The “gasping syndrome” is characterized by central nervous system (CNS) depression, metabolic acidosis, and gasping respirations. (Fachinformation zu Epoetin alfa, Warnhinweise und Vorsichtsmaßnahmen)

  • DimenhydrinatAntihistaminikumGeringfügig

    The “gasping syndrome” is characterized by central nervous system (CNS) depression, metabolic acidosis, and gasping respirations. (Fachinformation zu Epoetin alfa, Warnhinweise und Vorsichtsmaßnahmen)

  • DiphenhydraminAntihistaminikumGeringfügig

    The “gasping syndrome” is characterized by central nervous system (CNS) depression, metabolic acidosis, and gasping respirations. (Fachinformation zu Epoetin alfa, Warnhinweise und Vorsichtsmaßnahmen)

  • Doxepintrizyklisches AntidepressivumGeringfügig

    The “gasping syndrome” is characterized by central nervous system (CNS) depression, metabolic acidosis, and gasping respirations. (Fachinformation zu Epoetin alfa, Warnhinweise und Vorsichtsmaßnahmen)

  • DoxylaminAntihistaminikumGeringfügig

    The “gasping syndrome” is characterized by central nervous system (CNS) depression, metabolic acidosis, and gasping respirations. (Fachinformation zu Epoetin alfa, Warnhinweise und Vorsichtsmaßnahmen)

  • Doxylamin und PyridoxinAntihistaminikumGeringfügig

    The “gasping syndrome” is characterized by central nervous system (CNS) depression, metabolic acidosis, and gasping respirations. (Fachinformation zu Epoetin alfa, Warnhinweise und Vorsichtsmaßnahmen)

  • DronabinolCannabinoidGeringfügig

    The “gasping syndrome” is characterized by central nervous system (CNS) depression, metabolic acidosis, and gasping respirations. (Fachinformation zu Epoetin alfa, Warnhinweise und Vorsichtsmaßnahmen)

  • DroperidolDopaminantagonistGeringfügig

    The “gasping syndrome” is characterized by central nervous system (CNS) depression, metabolic acidosis, and gasping respirations. (Fachinformation zu Epoetin alfa, Warnhinweise und Vorsichtsmaßnahmen)

  • EslicarbazepinAntiepileptikumGeringfügig

    The “gasping syndrome” is characterized by central nervous system (CNS) depression, metabolic acidosis, and gasping respirations. (Fachinformation zu Epoetin alfa, Warnhinweise und Vorsichtsmaßnahmen)

  • EstazolamBenzodiazepinGeringfügig

    The “gasping syndrome” is characterized by central nervous system (CNS) depression, metabolic acidosis, and gasping respirations. (Fachinformation zu Epoetin alfa, Warnhinweise und Vorsichtsmaßnahmen)

  • EszopiclonSchlaf- und BeruhigungsmittelGeringfügig

    The “gasping syndrome” is characterized by central nervous system (CNS) depression, metabolic acidosis, and gasping respirations. (Fachinformation zu Epoetin alfa, Warnhinweise und Vorsichtsmaßnahmen)

  • EthosuximidAntiepileptikumGeringfügig

    The “gasping syndrome” is characterized by central nervous system (CNS) depression, metabolic acidosis, and gasping respirations. (Fachinformation zu Epoetin alfa, Warnhinweise und Vorsichtsmaßnahmen)

  • EtomidatAllgemeinanästhetikumGeringfügig

    The “gasping syndrome” is characterized by central nervous system (CNS) depression, metabolic acidosis, and gasping respirations. (Fachinformation zu Epoetin alfa, Warnhinweise und Vorsichtsmaßnahmen)

  • FelbamatAntiepileptikumGeringfügig

    The “gasping syndrome” is characterized by central nervous system (CNS) depression, metabolic acidosis, and gasping respirations. (Fachinformation zu Epoetin alfa, Warnhinweise und Vorsichtsmaßnahmen)

  • FentanylOpioidGeringfügig

    The “gasping syndrome” is characterized by central nervous system (CNS) depression, metabolic acidosis, and gasping respirations. (Fachinformation zu Epoetin alfa, Warnhinweise und Vorsichtsmaßnahmen)

  • FlibanserinZNS-dämpfendes ArzneimittelGeringfügig

    The “gasping syndrome” is characterized by central nervous system (CNS) depression, metabolic acidosis, and gasping respirations. (Fachinformation zu Epoetin alfa, Warnhinweise und Vorsichtsmaßnahmen)

  • FluphenazinAntipsychotikumGeringfügig

    The “gasping syndrome” is characterized by central nervous system (CNS) depression, metabolic acidosis, and gasping respirations. (Fachinformation zu Epoetin alfa, Warnhinweise und Vorsichtsmaßnahmen)

  • FosphenytoinAntiepileptikumGeringfügig

    The “gasping syndrome” is characterized by central nervous system (CNS) depression, metabolic acidosis, and gasping respirations. (Fachinformation zu Epoetin alfa, Warnhinweise und Vorsichtsmaßnahmen)

  • GabapentinAntiepileptikumGeringfügig

    The “gasping syndrome” is characterized by central nervous system (CNS) depression, metabolic acidosis, and gasping respirations. (Fachinformation zu Epoetin alfa, Warnhinweise und Vorsichtsmaßnahmen)

  • HaloperidolAntipsychotikumGeringfügig

    The “gasping syndrome” is characterized by central nervous system (CNS) depression, metabolic acidosis, and gasping respirations. (Fachinformation zu Epoetin alfa, Warnhinweise und Vorsichtsmaßnahmen)

  • HydrocodonOpioidGeringfügig

    The “gasping syndrome” is characterized by central nervous system (CNS) depression, metabolic acidosis, and gasping respirations. (Fachinformation zu Epoetin alfa, Warnhinweise und Vorsichtsmaßnahmen)

  • Hydrocodon und ChlorphenaminOpioidGeringfügig

    The “gasping syndrome” is characterized by central nervous system (CNS) depression, metabolic acidosis, and gasping respirations. (Fachinformation zu Epoetin alfa, Warnhinweise und Vorsichtsmaßnahmen)

  • Hydrocodon und HomatropinOpioidGeringfügig

    The “gasping syndrome” is characterized by central nervous system (CNS) depression, metabolic acidosis, and gasping respirations. (Fachinformation zu Epoetin alfa, Warnhinweise und Vorsichtsmaßnahmen)

  • Hydrocodon und IbuprofenOpioidGeringfügig

    The “gasping syndrome” is characterized by central nervous system (CNS) depression, metabolic acidosis, and gasping respirations. (Fachinformation zu Epoetin alfa, Warnhinweise und Vorsichtsmaßnahmen)

  • Hydrocodon und ParacetamolOpioidGeringfügig

    The “gasping syndrome” is characterized by central nervous system (CNS) depression, metabolic acidosis, and gasping respirations. (Fachinformation zu Epoetin alfa, Warnhinweise und Vorsichtsmaßnahmen)

  • HydromorphonOpioidGeringfügig

    The “gasping syndrome” is characterized by central nervous system (CNS) depression, metabolic acidosis, and gasping respirations. (Fachinformation zu Epoetin alfa, Warnhinweise und Vorsichtsmaßnahmen)

  • HydroxyzinAntihistaminikumGeringfügig

    The “gasping syndrome” is characterized by central nervous system (CNS) depression, metabolic acidosis, and gasping respirations. (Fachinformation zu Epoetin alfa, Warnhinweise und Vorsichtsmaßnahmen)

  • IloperidonAntipsychotikumGeringfügig

    The “gasping syndrome” is characterized by central nervous system (CNS) depression, metabolic acidosis, and gasping respirations. (Fachinformation zu Epoetin alfa, Warnhinweise und Vorsichtsmaßnahmen)

  • Imipramintrizyklisches AntidepressivumGeringfügig

    The “gasping syndrome” is characterized by central nervous system (CNS) depression, metabolic acidosis, and gasping respirations. (Fachinformation zu Epoetin alfa, Warnhinweise und Vorsichtsmaßnahmen)

  • IsofluranAllgemeinanästhetikumGeringfügig

    The “gasping syndrome” is characterized by central nervous system (CNS) depression, metabolic acidosis, and gasping respirations. (Fachinformation zu Epoetin alfa, Warnhinweise und Vorsichtsmaßnahmen)

  • KetaminZNS-dämpfendes ArzneimittelGeringfügig

    The “gasping syndrome” is characterized by central nervous system (CNS) depression, metabolic acidosis, and gasping respirations. (Fachinformation zu Epoetin alfa, Warnhinweise und Vorsichtsmaßnahmen)

  • LacosamidAntiepileptikumGeringfügig

    The “gasping syndrome” is characterized by central nervous system (CNS) depression, metabolic acidosis, and gasping respirations. (Fachinformation zu Epoetin alfa, Warnhinweise und Vorsichtsmaßnahmen)

  • LemborexantSchlaf- und BeruhigungsmittelGeringfügig

    The “gasping syndrome” is characterized by central nervous system (CNS) depression, metabolic acidosis, and gasping respirations. (Fachinformation zu Epoetin alfa, Warnhinweise und Vorsichtsmaßnahmen)

  • LevetiracetamAntiepileptikumGeringfügig

    The “gasping syndrome” is characterized by central nervous system (CNS) depression, metabolic acidosis, and gasping respirations. (Fachinformation zu Epoetin alfa, Warnhinweise und Vorsichtsmaßnahmen)

  • LevorphanolOpioidGeringfügig

    The “gasping syndrome” is characterized by central nervous system (CNS) depression, metabolic acidosis, and gasping respirations. (Fachinformation zu Epoetin alfa, Warnhinweise und Vorsichtsmaßnahmen)

  • LorazepamBenzodiazepinGeringfügig

    The “gasping syndrome” is characterized by central nervous system (CNS) depression, metabolic acidosis, and gasping respirations. (Fachinformation zu Epoetin alfa, Warnhinweise und Vorsichtsmaßnahmen)

  • LoxapinAntipsychotikumGeringfügig

    The “gasping syndrome” is characterized by central nervous system (CNS) depression, metabolic acidosis, and gasping respirations. (Fachinformation zu Epoetin alfa, Warnhinweise und Vorsichtsmaßnahmen)

  • LumateperonAntipsychotikumGeringfügig

    The “gasping syndrome” is characterized by central nervous system (CNS) depression, metabolic acidosis, and gasping respirations. (Fachinformation zu Epoetin alfa, Warnhinweise und Vorsichtsmaßnahmen)

  • LurasidonAntipsychotikumGeringfügig

    The “gasping syndrome” is characterized by central nervous system (CNS) depression, metabolic acidosis, and gasping respirations. (Fachinformation zu Epoetin alfa, Warnhinweise und Vorsichtsmaßnahmen)

  • MeclozinAntihistaminikumGeringfügig

    The “gasping syndrome” is characterized by central nervous system (CNS) depression, metabolic acidosis, and gasping respirations. (Fachinformation zu Epoetin alfa, Warnhinweise und Vorsichtsmaßnahmen)

  • MeprobamatZNS-dämpfendes ArzneimittelGeringfügig

    The “gasping syndrome” is characterized by central nervous system (CNS) depression, metabolic acidosis, and gasping respirations. (Fachinformation zu Epoetin alfa, Warnhinweise und Vorsichtsmaßnahmen)

  • MesuximidAntiepileptikumGeringfügig

    The “gasping syndrome” is characterized by central nervous system (CNS) depression, metabolic acidosis, and gasping respirations. (Fachinformation zu Epoetin alfa, Warnhinweise und Vorsichtsmaßnahmen)

  • MetaxalonMuskelrelaxansGeringfügig

    The “gasping syndrome” is characterized by central nervous system (CNS) depression, metabolic acidosis, and gasping respirations. (Fachinformation zu Epoetin alfa, Warnhinweise und Vorsichtsmaßnahmen)

  • MethadonOpioidGeringfügig

    The “gasping syndrome” is characterized by central nervous system (CNS) depression, metabolic acidosis, and gasping respirations. (Fachinformation zu Epoetin alfa, Warnhinweise und Vorsichtsmaßnahmen)

  • MethocarbamolMuskelrelaxansGeringfügig

    The “gasping syndrome” is characterized by central nervous system (CNS) depression, metabolic acidosis, and gasping respirations. (Fachinformation zu Epoetin alfa, Warnhinweise und Vorsichtsmaßnahmen)

  • MethohexitalBarbituratGeringfügig

    The “gasping syndrome” is characterized by central nervous system (CNS) depression, metabolic acidosis, and gasping respirations. (Fachinformation zu Epoetin alfa, Warnhinweise und Vorsichtsmaßnahmen)

  • MetoclopramidDopaminantagonistGeringfügig

    The “gasping syndrome” is characterized by central nervous system (CNS) depression, metabolic acidosis, and gasping respirations. (Fachinformation zu Epoetin alfa, Warnhinweise und Vorsichtsmaßnahmen)

  • MidazolamBenzodiazepinGeringfügig

    The “gasping syndrome” is characterized by central nervous system (CNS) depression, metabolic acidosis, and gasping respirations. (Fachinformation zu Epoetin alfa, Warnhinweise und Vorsichtsmaßnahmen)

  • MirtazapinAntidepressivumGeringfügig

    The “gasping syndrome” is characterized by central nervous system (CNS) depression, metabolic acidosis, and gasping respirations. (Fachinformation zu Epoetin alfa, Warnhinweise und Vorsichtsmaßnahmen)

  • MorphinOpioidGeringfügig

    The “gasping syndrome” is characterized by central nervous system (CNS) depression, metabolic acidosis, and gasping respirations. (Fachinformation zu Epoetin alfa, Warnhinweise und Vorsichtsmaßnahmen)

  • NalbuphinOpioidGeringfügig

    The “gasping syndrome” is characterized by central nervous system (CNS) depression, metabolic acidosis, and gasping respirations. (Fachinformation zu Epoetin alfa, Warnhinweise und Vorsichtsmaßnahmen)

  • NatriumoxybatZNS-dämpfendes ArzneimittelGeringfügig

    The “gasping syndrome” is characterized by central nervous system (CNS) depression, metabolic acidosis, and gasping respirations. (Fachinformation zu Epoetin alfa, Warnhinweise und Vorsichtsmaßnahmen)

  • Nortriptylintrizyklisches AntidepressivumGeringfügig

    The “gasping syndrome” is characterized by central nervous system (CNS) depression, metabolic acidosis, and gasping respirations. (Fachinformation zu Epoetin alfa, Warnhinweise und Vorsichtsmaßnahmen)

  • OlanzapinAntipsychotikumGeringfügig

    The “gasping syndrome” is characterized by central nervous system (CNS) depression, metabolic acidosis, and gasping respirations. (Fachinformation zu Epoetin alfa, Warnhinweise und Vorsichtsmaßnahmen)

  • Olanzapin und FluoxetinAntipsychotikumGeringfügig

    The “gasping syndrome” is characterized by central nervous system (CNS) depression, metabolic acidosis, and gasping respirations. (Fachinformation zu Epoetin alfa, Warnhinweise und Vorsichtsmaßnahmen)

  • OliceridinOpioidGeringfügig

    The “gasping syndrome” is characterized by central nervous system (CNS) depression, metabolic acidosis, and gasping respirations. (Fachinformation zu Epoetin alfa, Warnhinweise und Vorsichtsmaßnahmen)

  • OrphenadrinMuskelrelaxansGeringfügig

    The “gasping syndrome” is characterized by central nervous system (CNS) depression, metabolic acidosis, and gasping respirations. (Fachinformation zu Epoetin alfa, Warnhinweise und Vorsichtsmaßnahmen)

  • Orphenadrin, Acetylsalicylsäure und KoffeinMuskelrelaxansGeringfügig

    The “gasping syndrome” is characterized by central nervous system (CNS) depression, metabolic acidosis, and gasping respirations. (Fachinformation zu Epoetin alfa, Warnhinweise und Vorsichtsmaßnahmen)

  • OxazepamBenzodiazepinGeringfügig

    The “gasping syndrome” is characterized by central nervous system (CNS) depression, metabolic acidosis, and gasping respirations. (Fachinformation zu Epoetin alfa, Warnhinweise und Vorsichtsmaßnahmen)

  • OxcarbazepinAntiepileptikumGeringfügig

    The “gasping syndrome” is characterized by central nervous system (CNS) depression, metabolic acidosis, and gasping respirations. (Fachinformation zu Epoetin alfa, Warnhinweise und Vorsichtsmaßnahmen)

  • OxycodonOpioidGeringfügig

    The “gasping syndrome” is characterized by central nervous system (CNS) depression, metabolic acidosis, and gasping respirations. (Fachinformation zu Epoetin alfa, Warnhinweise und Vorsichtsmaßnahmen)

  • Oxycodon und ParacetamolOpioidGeringfügig

    The “gasping syndrome” is characterized by central nervous system (CNS) depression, metabolic acidosis, and gasping respirations. (Fachinformation zu Epoetin alfa, Warnhinweise und Vorsichtsmaßnahmen)

  • OxymorphonOpioidGeringfügig

    The “gasping syndrome” is characterized by central nervous system (CNS) depression, metabolic acidosis, and gasping respirations. (Fachinformation zu Epoetin alfa, Warnhinweise und Vorsichtsmaßnahmen)

  • PaliperidonAntipsychotikumGeringfügig

    The “gasping syndrome” is characterized by central nervous system (CNS) depression, metabolic acidosis, and gasping respirations. (Fachinformation zu Epoetin alfa, Warnhinweise und Vorsichtsmaßnahmen)

  • Paracetamol und CodeinOpioidGeringfügig

    The “gasping syndrome” is characterized by central nervous system (CNS) depression, metabolic acidosis, and gasping respirations. (Fachinformation zu Epoetin alfa, Warnhinweise und Vorsichtsmaßnahmen)

  • Pentazocin und NaloxonOpioidGeringfügig

    The “gasping syndrome” is characterized by central nervous system (CNS) depression, metabolic acidosis, and gasping respirations. (Fachinformation zu Epoetin alfa, Warnhinweise und Vorsichtsmaßnahmen)

  • PerampanelAntiepileptikumGeringfügig

    The “gasping syndrome” is characterized by central nervous system (CNS) depression, metabolic acidosis, and gasping respirations. (Fachinformation zu Epoetin alfa, Warnhinweise und Vorsichtsmaßnahmen)

  • PerphenazinAntipsychotikumGeringfügig

    The “gasping syndrome” is characterized by central nervous system (CNS) depression, metabolic acidosis, and gasping respirations. (Fachinformation zu Epoetin alfa, Warnhinweise und Vorsichtsmaßnahmen)

  • PethidinOpioidGeringfügig

    The “gasping syndrome” is characterized by central nervous system (CNS) depression, metabolic acidosis, and gasping respirations. (Fachinformation zu Epoetin alfa, Warnhinweise und Vorsichtsmaßnahmen)

  • PhenobarbitalBarbituratGeringfügig

    The “gasping syndrome” is characterized by central nervous system (CNS) depression, metabolic acidosis, and gasping respirations. (Fachinformation zu Epoetin alfa, Warnhinweise und Vorsichtsmaßnahmen)

  • Phenobarbital, Hyoscyamin, Atropin und ScopolaminBarbituratGeringfügig

    The “gasping syndrome” is characterized by central nervous system (CNS) depression, metabolic acidosis, and gasping respirations. (Fachinformation zu Epoetin alfa, Warnhinweise und Vorsichtsmaßnahmen)

  • Phentermin und TopiramatZNS-StimulansGeringfügig

    The “gasping syndrome” is characterized by central nervous system (CNS) depression, metabolic acidosis, and gasping respirations. (Fachinformation zu Epoetin alfa, Warnhinweise und Vorsichtsmaßnahmen)

  • PhenytoinAntiepileptikumGeringfügig

    The “gasping syndrome” is characterized by central nervous system (CNS) depression, metabolic acidosis, and gasping respirations. (Fachinformation zu Epoetin alfa, Warnhinweise und Vorsichtsmaßnahmen)

  • PimozidAntipsychotikumGeringfügig

    The “gasping syndrome” is characterized by central nervous system (CNS) depression, metabolic acidosis, and gasping respirations. (Fachinformation zu Epoetin alfa, Warnhinweise und Vorsichtsmaßnahmen)

  • PramipexolDopaminagonistGeringfügig

    The “gasping syndrome” is characterized by central nervous system (CNS) depression, metabolic acidosis, and gasping respirations. (Fachinformation zu Epoetin alfa, Warnhinweise und Vorsichtsmaßnahmen)

  • PregabalinAntiepileptikumGeringfügig

    The “gasping syndrome” is characterized by central nervous system (CNS) depression, metabolic acidosis, and gasping respirations. (Fachinformation zu Epoetin alfa, Warnhinweise und Vorsichtsmaßnahmen)

  • PrimidonAntiepileptikumGeringfügig

    The “gasping syndrome” is characterized by central nervous system (CNS) depression, metabolic acidosis, and gasping respirations. (Fachinformation zu Epoetin alfa, Warnhinweise und Vorsichtsmaßnahmen)

  • ProchlorperazinAntipsychotikumGeringfügig

    The “gasping syndrome” is characterized by central nervous system (CNS) depression, metabolic acidosis, and gasping respirations. (Fachinformation zu Epoetin alfa, Warnhinweise und Vorsichtsmaßnahmen)

  • PromethazinAntihistaminikumGeringfügig

    The “gasping syndrome” is characterized by central nervous system (CNS) depression, metabolic acidosis, and gasping respirations. (Fachinformation zu Epoetin alfa, Warnhinweise und Vorsichtsmaßnahmen)

  • Promethazin und CodeinOpioidGeringfügig

    The “gasping syndrome” is characterized by central nervous system (CNS) depression, metabolic acidosis, and gasping respirations. (Fachinformation zu Epoetin alfa, Warnhinweise und Vorsichtsmaßnahmen)

  • Promethazin und DextromethorphanAntihistaminikumGeringfügig

    The “gasping syndrome” is characterized by central nervous system (CNS) depression, metabolic acidosis, and gasping respirations. (Fachinformation zu Epoetin alfa, Warnhinweise und Vorsichtsmaßnahmen)

  • PropofolZNS-dämpfendes ArzneimittelGeringfügig

    The “gasping syndrome” is characterized by central nervous system (CNS) depression, metabolic acidosis, and gasping respirations. (Fachinformation zu Epoetin alfa, Warnhinweise und Vorsichtsmaßnahmen)

  • Protriptylintrizyklisches AntidepressivumGeringfügig

    The “gasping syndrome” is characterized by central nervous system (CNS) depression, metabolic acidosis, and gasping respirations. (Fachinformation zu Epoetin alfa, Warnhinweise und Vorsichtsmaßnahmen)

  • QuetiapinAntipsychotikumGeringfügig

    The “gasping syndrome” is characterized by central nervous system (CNS) depression, metabolic acidosis, and gasping respirations. (Fachinformation zu Epoetin alfa, Warnhinweise und Vorsichtsmaßnahmen)

  • RamelteonSchlaf- und BeruhigungsmittelGeringfügig

    The “gasping syndrome” is characterized by central nervous system (CNS) depression, metabolic acidosis, and gasping respirations. (Fachinformation zu Epoetin alfa, Warnhinweise und Vorsichtsmaßnahmen)

  • RemifentanilOpioidGeringfügig

    The “gasping syndrome” is characterized by central nervous system (CNS) depression, metabolic acidosis, and gasping respirations. (Fachinformation zu Epoetin alfa, Warnhinweise und Vorsichtsmaßnahmen)

  • RisperidonAntipsychotikumGeringfügig

    The “gasping syndrome” is characterized by central nervous system (CNS) depression, metabolic acidosis, and gasping respirations. (Fachinformation zu Epoetin alfa, Warnhinweise und Vorsichtsmaßnahmen)

  • RopinirolDopaminagonistGeringfügig

    The “gasping syndrome” is characterized by central nervous system (CNS) depression, metabolic acidosis, and gasping respirations. (Fachinformation zu Epoetin alfa, Warnhinweise und Vorsichtsmaßnahmen)

  • RufinamidAntiepileptikumGeringfügig

    The “gasping syndrome” is characterized by central nervous system (CNS) depression, metabolic acidosis, and gasping respirations. (Fachinformation zu Epoetin alfa, Warnhinweise und Vorsichtsmaßnahmen)

  • ScopolaminAnticholinergikumGeringfügig

    The “gasping syndrome” is characterized by central nervous system (CNS) depression, metabolic acidosis, and gasping respirations. (Fachinformation zu Epoetin alfa, Warnhinweise und Vorsichtsmaßnahmen)

  • SevofluranAllgemeinanästhetikumGeringfügig

    The “gasping syndrome” is characterized by central nervous system (CNS) depression, metabolic acidosis, and gasping respirations. (Fachinformation zu Epoetin alfa, Warnhinweise und Vorsichtsmaßnahmen)

  • SuvorexantSchlaf- und BeruhigungsmittelGeringfügig

    The “gasping syndrome” is characterized by central nervous system (CNS) depression, metabolic acidosis, and gasping respirations. (Fachinformation zu Epoetin alfa, Warnhinweise und Vorsichtsmaßnahmen)

  • TapentadolOpioidGeringfügig

    The “gasping syndrome” is characterized by central nervous system (CNS) depression, metabolic acidosis, and gasping respirations. (Fachinformation zu Epoetin alfa, Warnhinweise und Vorsichtsmaßnahmen)

  • TasimelteonSchlaf- und BeruhigungsmittelGeringfügig

    The “gasping syndrome” is characterized by central nervous system (CNS) depression, metabolic acidosis, and gasping respirations. (Fachinformation zu Epoetin alfa, Warnhinweise und Vorsichtsmaßnahmen)

  • TemazepamBenzodiazepinGeringfügig

    The “gasping syndrome” is characterized by central nervous system (CNS) depression, metabolic acidosis, and gasping respirations. (Fachinformation zu Epoetin alfa, Warnhinweise und Vorsichtsmaßnahmen)

  • TetrabenazinVMAT2-HemmerGeringfügig

    The “gasping syndrome” is characterized by central nervous system (CNS) depression, metabolic acidosis, and gasping respirations. (Fachinformation zu Epoetin alfa, Warnhinweise und Vorsichtsmaßnahmen)

  • ThioridazinAntipsychotikumGeringfügig

    The “gasping syndrome” is characterized by central nervous system (CNS) depression, metabolic acidosis, and gasping respirations. (Fachinformation zu Epoetin alfa, Warnhinweise und Vorsichtsmaßnahmen)

  • TiagabinAntiepileptikumGeringfügig

    The “gasping syndrome” is characterized by central nervous system (CNS) depression, metabolic acidosis, and gasping respirations. (Fachinformation zu Epoetin alfa, Warnhinweise und Vorsichtsmaßnahmen)

  • TiotixenAntipsychotikumGeringfügig

    The “gasping syndrome” is characterized by central nervous system (CNS) depression, metabolic acidosis, and gasping respirations. (Fachinformation zu Epoetin alfa, Warnhinweise und Vorsichtsmaßnahmen)

  • TopiramatAntiepileptikumGeringfügig

    The “gasping syndrome” is characterized by central nervous system (CNS) depression, metabolic acidosis, and gasping respirations. (Fachinformation zu Epoetin alfa, Warnhinweise und Vorsichtsmaßnahmen)

  • TramadolOpioidGeringfügig

    The “gasping syndrome” is characterized by central nervous system (CNS) depression, metabolic acidosis, and gasping respirations. (Fachinformation zu Epoetin alfa, Warnhinweise und Vorsichtsmaßnahmen)

  • Tramadol und ParacetamolOpioidGeringfügig

    The “gasping syndrome” is characterized by central nervous system (CNS) depression, metabolic acidosis, and gasping respirations. (Fachinformation zu Epoetin alfa, Warnhinweise und Vorsichtsmaßnahmen)

  • TrazodonAntidepressivumGeringfügig

    The “gasping syndrome” is characterized by central nervous system (CNS) depression, metabolic acidosis, and gasping respirations. (Fachinformation zu Epoetin alfa, Warnhinweise und Vorsichtsmaßnahmen)

  • TriazolamBenzodiazepinGeringfügig

    The “gasping syndrome” is characterized by central nervous system (CNS) depression, metabolic acidosis, and gasping respirations. (Fachinformation zu Epoetin alfa, Warnhinweise und Vorsichtsmaßnahmen)

  • TrifluoperazinAntipsychotikumGeringfügig

    The “gasping syndrome” is characterized by central nervous system (CNS) depression, metabolic acidosis, and gasping respirations. (Fachinformation zu Epoetin alfa, Warnhinweise und Vorsichtsmaßnahmen)

  • Trimipramintrizyklisches AntidepressivumGeringfügig

    The “gasping syndrome” is characterized by central nervous system (CNS) depression, metabolic acidosis, and gasping respirations. (Fachinformation zu Epoetin alfa, Warnhinweise und Vorsichtsmaßnahmen)

  • Valproat-Seminatrium (Divalproex)AntiepileptikumGeringfügig

    The “gasping syndrome” is characterized by central nervous system (CNS) depression, metabolic acidosis, and gasping respirations. (Fachinformation zu Epoetin alfa, Warnhinweise und Vorsichtsmaßnahmen)

  • ValproinsäureAntiepileptikumGeringfügig

    The “gasping syndrome” is characterized by central nervous system (CNS) depression, metabolic acidosis, and gasping respirations. (Fachinformation zu Epoetin alfa, Warnhinweise und Vorsichtsmaßnahmen)

  • VigabatrinAntiepileptikumGeringfügig

    The “gasping syndrome” is characterized by central nervous system (CNS) depression, metabolic acidosis, and gasping respirations. (Fachinformation zu Epoetin alfa, Warnhinweise und Vorsichtsmaßnahmen)

  • ZaleplonSchlaf- und BeruhigungsmittelGeringfügig

    The “gasping syndrome” is characterized by central nervous system (CNS) depression, metabolic acidosis, and gasping respirations. (Fachinformation zu Epoetin alfa, Warnhinweise und Vorsichtsmaßnahmen)

  • ZiprasidonAntipsychotikumGeringfügig

    The “gasping syndrome” is characterized by central nervous system (CNS) depression, metabolic acidosis, and gasping respirations. (Fachinformation zu Epoetin alfa, Warnhinweise und Vorsichtsmaßnahmen)

  • ZolpidemSchlaf- und BeruhigungsmittelGeringfügig

    The “gasping syndrome” is characterized by central nervous system (CNS) depression, metabolic acidosis, and gasping respirations. (Fachinformation zu Epoetin alfa, Warnhinweise und Vorsichtsmaßnahmen)

  • ZonisamidAntiepileptikumGeringfügig

    The “gasping syndrome” is characterized by central nervous system (CNS) depression, metabolic acidosis, and gasping respirations. (Fachinformation zu Epoetin alfa, Warnhinweise und Vorsichtsmaßnahmen)

Prüfen Sie Epoetin alfa gegen alles, was Sie einnehmen. Fügen Sie Ihre gesamte Liste hinzu; alle Paare werden auf einmal geprüft.

Im Wechselwirkungscheck öffnen

Keine medizinische Beratung. Der Schweregrad gibt die Formulierung der Fachinformation wieder, nicht Ihre persönlichen Umstände. Eine als „schwerwiegend“ eingestufte Wechselwirkung kann unter Aufsicht Routine sein, und eine „geringfügige“ kann bei hohen Dosen von Bedeutung sein. Fragen Sie in einer Apotheke nach.